Actuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Pancreatic Cancer

Elraglusib is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta inhibitor which is being developed for adults and children with advanced refractory cancers.